 Daisy Alapat
Concepts (97)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 9 | 2024 | 2916 | 0.530 |
Why?
| | Gene Rearrangement, B-Lymphocyte | 1 | 2015 | 6 | 0.490 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2015 | 7 | 0.490 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 103 | 0.450 |
Why?
| | Plasma Cells | 1 | 2015 | 221 | 0.440 |
Why?
| | Tumor Microenvironment | 3 | 2024 | 221 | 0.420 |
Why?
| | Cell Differentiation | 1 | 2015 | 649 | 0.390 |
Why?
| | Carcinoembryonic Antigen | 1 | 2011 | 14 | 0.370 |
Why?
| | Calcitonin | 1 | 2011 | 30 | 0.370 |
Why?
| | Carcinoma | 1 | 2011 | 139 | 0.330 |
Why?
| | Myogenin | 1 | 2008 | 4 | 0.320 |
Why?
| | Muscle Fibers, Slow-Twitch | 1 | 2008 | 12 | 0.320 |
Why?
| | Muscle Fibers, Fast-Twitch | 1 | 2008 | 14 | 0.320 |
Why?
| | Flow Cytometry | 2 | 2016 | 470 | 0.210 |
Why?
| | Gene Expression Profiling | 2 | 2016 | 1028 | 0.180 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 2 | 2024 | 111 | 0.180 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2024 | 555 | 0.160 |
Why?
| | Bone Marrow | 1 | 2020 | 351 | 0.160 |
Why?
| | Immunoglobulins | 1 | 2016 | 79 | 0.130 |
Why?
| | V(D)J Recombination | 1 | 2015 | 4 | 0.120 |
Why?
| | Immunoglobulin Light Chains | 1 | 2015 | 82 | 0.120 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 321 | 0.110 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 456 | 0.110 |
Why?
| | Pancytopenia | 2 | 2013 | 36 | 0.110 |
Why?
| | Humans | 13 | 2024 | 49929 | 0.110 |
Why?
| | Parvoviridae Infections | 1 | 2013 | 20 | 0.110 |
Why?
| | Parvovirus B19, Human | 1 | 2013 | 17 | 0.110 |
Why?
| | Partial Thromboplastin Time | 1 | 2012 | 12 | 0.110 |
Why?
| | Prothrombin Time | 1 | 2012 | 18 | 0.110 |
Why?
| | Lymph Nodes | 1 | 2015 | 257 | 0.100 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2013 | 55 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2016 | 824 | 0.100 |
Why?
| | Glycoproteins | 1 | 2012 | 115 | 0.100 |
Why?
| | Paraproteinemias | 1 | 2012 | 71 | 0.100 |
Why?
| | Middle Aged | 6 | 2020 | 12293 | 0.100 |
Why?
| | Prognosis | 3 | 2024 | 1957 | 0.090 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2011 | 23 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 1354 | 0.090 |
Why?
| | Splenic Neoplasms | 1 | 2009 | 2 | 0.090 |
Why?
| | Male | 7 | 2024 | 25454 | 0.090 |
Why?
| | Thyroid Neoplasms | 1 | 2011 | 112 | 0.080 |
Why?
| | Myelodysplastic Syndromes | 1 | 2009 | 79 | 0.080 |
Why?
| | Female | 8 | 2024 | 26576 | 0.080 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2008 | 98 | 0.080 |
Why?
| | Hemangioma | 1 | 2009 | 83 | 0.080 |
Why?
| | Protein Processing, Post-Translational | 1 | 2008 | 154 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2008 | 1587 | 0.070 |
Why?
| | Muscle Proteins | 1 | 2008 | 316 | 0.060 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2005 | 36 | 0.060 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 96 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 1175 | 0.060 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2005 | 131 | 0.060 |
Why?
| | Imidazoles | 1 | 2005 | 128 | 0.060 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 107 | 0.060 |
Why?
| | Ferritins | 1 | 2024 | 30 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2013 | 5178 | 0.060 |
Why?
| | Pyridines | 1 | 2005 | 133 | 0.060 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 17 | 0.060 |
Why?
| | Pyrimidines | 1 | 2005 | 192 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 964 | 0.060 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 124 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2005 | 378 | 0.050 |
Why?
| | Transplantation, Autologous | 1 | 2024 | 462 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2023 | 328 | 0.050 |
Why?
| | Aged | 4 | 2016 | 9449 | 0.050 |
Why?
| | Tumor Burden | 1 | 2020 | 131 | 0.040 |
Why?
| | Disease Progression | 2 | 2016 | 820 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 1388 | 0.040 |
Why?
| | Adolescent | 1 | 2011 | 6417 | 0.040 |
Why?
| | Cohort Studies | 1 | 2020 | 1403 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 36 | 0.030 |
Why?
| | Melphalan | 1 | 2016 | 173 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 450 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 181 | 0.030 |
Why?
| | Thalidomide | 1 | 2016 | 374 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 579 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 409 | 0.030 |
Why?
| | Mice | 1 | 2023 | 5658 | 0.030 |
Why?
| | Fibrinogen | 1 | 2012 | 32 | 0.030 |
Why?
| | Adult | 2 | 2020 | 13356 | 0.030 |
Why?
| | Blood Coagulation | 1 | 2012 | 58 | 0.030 |
Why?
| | Survival Rate | 1 | 2015 | 905 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2015 | 749 | 0.030 |
Why?
| | Reference Values | 1 | 2012 | 302 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2013 | 179 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2024 | 6124 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2015 | 1099 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 994 | 0.020 |
Why?
| | Splenectomy | 1 | 2009 | 34 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2012 | 953 | 0.020 |
Why?
| | Embolization, Therapeutic | 1 | 2009 | 85 | 0.020 |
Why?
| | Blood Transfusion | 1 | 2009 | 125 | 0.020 |
Why?
| | Animals | 1 | 2023 | 13100 | 0.020 |
Why?
| | Laparoscopy | 1 | 2009 | 170 | 0.020 |
Why?
| | Cell Division | 1 | 2005 | 294 | 0.010 |
Why?
| | Phosphorylation | 1 | 2005 | 526 | 0.010 |
Why?
| | Cell Survival | 1 | 2005 | 590 | 0.010 |
Why?
|
|
Alapat's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|